集成治疗纳米平台通过放射性核素标记的NIR-II聚集诱导的发射发光体实现癌症的精确治疗
Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.
摘要(中文译文)
恶性肿瘤常因其复杂性和高复发率而逃避常规治疗。为克服这些局限，本研究通过对近红外二区（NIR-II）发射的聚集诱导发光光敏剂进行叶酸和多齿配体（DOTA）修饰，随后用Ga进行放射性标记，构建了一个集成诊疗纳米平台。该策略不仅增强了肿瘤靶向精度，还赋予纳米颗粒（[Ga]DOTA-FA-BBTD-4C NPs）优越的正电子发射断层扫描/计算机断层扫描（PET/CT）成像能力。该纳米颗粒在胶质母细胞瘤细胞中对叶酸受体α表现出特异性靶向和高亲和力结合，在注射后0.5小时即可通过PET/CT成像实现清晰的肿瘤 delineation，并在12小时手术窗口内实现荧光成像引导的精确肿瘤切除。此外，基于AIE活性光敏剂的平台同时通过局部热疗和活性氧生成介导协同光疗，有效诱导凋亡和细胞周期阻滞，从而在雌性小鼠模型中预防肿瘤复发。这一多功能诊疗纳米平台代表了癌症诊断和治疗的进步，为临床应用提供了有前景的转化潜力。
Abstract
Malignant tumours frequently evade conventional therapies due to their complexity and high recurrence rates. To overcome these limitations, an integrated theranostic nanoplatform was developed through modification of a NIR-II emitting aggregation-induced emission photosensitizer with folic acid and the polydentate ligand (DOTA), followed by radiolabeling with Ga. This strategy not only enhances cancer targeting precision but also confers superior positron emission tomography/computed tomography (PET/CT) imaging capabilities to the nanoparticles ([Ga]DOTA-FA-BBTD-4C NPs). This nanoparticle demonstrates specific targeting and high-affinity binding to folate receptor alpha in glioblastoma cells, achieving clear tumour delineation by PET/CT imaging at 0.5 h post-injection and enabling accurate tumour resection guided by fluorescence imaging within a 12-h surgical window. Furthermore, the AIE-active photosensitizer-based platform simultaneously mediates synergistic phototherapy through localised hyperthermia and reactive oxygen species generation, effectively inducing apoptosis and cell cycle arrest to prevent tumour recurrence in female mice model. This multifunctional theranostic nanoplatform represents an advancement in cancer diagnosis and treatment, offering promising translational potential for clinical applications.
如何引用
AMA
Guo-Ling Zhang, Da-Yong Hou, Yixuan Chen, Pu Chen, Jiong-Cheng Wu, Yue-Ze Wang, et al. Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.. Nature communications. 2026; doi:10.1038/s41467-026-74359-4.
APA
Guo-Ling Zhang, Da-Yong Hou, Yixuan Chen, Pu Chen, Jiong-Cheng Wu, Yue-Ze Wang, et al (2026). Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.. Nature communications. https://doi.org/10.1038/s41467-026-74359-4
GB/T 7714
Guo-Ling Zhang, Da-Yong Hou, Yixuan Chen, Pu Chen, Jiong-Cheng Wu, Yue-Ze Wang, et al. Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.[J]. Nature communications, 2026 doi:10.1038/s41467-026-74359-4.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出